Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks

Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures.

Cofactor Genomics Advances Predictive Cancer Diagnostics With Landmark OncoPrism-NSCLC Study

Cofactor Genomics, a leader in cancer immunotherapy predictive diagnostics, today announced results from the PREDAPT non-small cell lung cancer (NSCLC) trial validating the company’s OncoPrism-NSCLC ...
Business Wire

Cofactor Genomics’ Immunotherapy Predictive Diagnostic, OncoPrism, Completes Validation and Moves Into Clinical Use in Head and Neck Cancer Patients

SAINT LOUIS, Mo.--(BUSINESS WIRE)--Cofactor Genomics, the company bridging the precision medicine gap, today announced successful validation of the OncoPrism immunotherapy predictive diagnostic assay, ...
Business Wire

Cofactor Genomics Announces the Expansion of OncoPrism into Colorectal, Breast, Bladder, and Kidney Cancer

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics announced today OncoPrism for colorectal, breast, bladder, and kidney cancer. This announcement follows recent Medicare coverage of the OncoPrism ...
Crain's Chicago Business

Startup focused on fast-tracking health care appeals raises $4M

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Cofactor AI has created software that uses artificial ...